(Date:3/12/2010)... in medical device package, product and material testing, is taking strides ... Francis to division manager. , ... Minneapolis, MN (PRWEB) ... package, product and material testing, is taking strides to expand their ... manager. , , ,DDL has been helping medical device manufacturers ...
(Date:3/11/2010)... announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic ... ... , , ... ... ...
(Date:3/11/2010)... 11, 2010 Azur Pharma Limited ("Azur") today announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan ... ... , ... ... ...
(Date:3/11/2010)... March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing ... agreements with University Health Network (UHN) and The Hospital for Sick Children (SickKids) ... immunology programs in the areas of hematopoietic stem cell transplantation and cancer. , ... ... ...
Breaking Biology Technology:DDL Expands the Product & Material Testing Division 2DDL Expands the Product & Material Testing Division 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3... Inc., 2000 Alfred Nobel Drive,Hercules, CA 94547 USA , ... Real-Time PCR , ... , in the technology and associated equipment have ... today relative to earlier protocols. One of the , ...
... Giles Cunnick and Wen Guo Jiang, Metastasis Research Group, University,Department of ... , Introduction ... of new lymphatic vessels. This , process ... to spreading by direct invasion and via the bloodstream, ...
... Qian Gao, Joella Blas, and Efthalia Gerasimopoulos, Bio-Rad Laboratories, Inc.,Hercules, CA 94547 USA ... Introduction , ... volume of sample. The assays are based on detection ... (xMAP technology) that have bound to each target protein. , ...
Other Biology Technology:The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 2The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 4The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 5The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 6The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 7The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 8Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A 2Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A 3Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A 4Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A 5Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays 2Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays 3Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays 4RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
Request Info...
... provides all the materials necessary for the isolation ... antigen studies analysis. Kit Components: ... 5122) One bottle containing 220 mL of buffered ... (5X) - (Catalog No. 5113) One bottle containing ...
... use with suspension (non-adherent) cells, ... vacuum filtration or centrifugation to ... Compatible with 96-well GenePlate®. ... larger package sizes and contain ...
Biology Products:Biology NavigationMedical Navigation